Maria Dobek Biography and Net Worth

VP of Janux Therapeutics

Maria joined Janux in March 2021 prior to the company’s IPO. In her current role as Vice President, Accounting, she leads the accounting function including overseeing the company’s financial reporting, technical accounting and compliance with Sarbanes-Oxley. Prior to joining Janux, Maria worked in various roles of increasing responsibility for over 9 years at Ernst & Young, LLP, most recently as Assurance Senior Manager. During her tenure at E&Y, Maria led financial statement audits, assisted clients with first year SOX 404(b) implementations as well as SEC filings and registrations, including initial public offerings, secondary offerings and debt offerings. Primarily serving clients in the life science sector while at E&Y, her clients ranged in size from venture capital backed start-up companies to multi-billion-dollar market cap SEC registrants.

Maria holds a Bachelor of Business Administration and Master’s degree in Accounting from the University of Georgia. She is a Certified Public Accountant in the State of California.

What is Maria Dobek's net worth?: The estimated net worth of Maria Dobek is at least $207.37 thousand as of January 2nd, 2026. Dobek owns 15,373 shares of Janux Therapeutics stock worth more than $207,366 as of February 18th. This net worth estimate does not reflect any other assets that Dobek may own. Learn More about Maria Dobek's net worth.
How do I contact Maria Dobek?: The corporate mailing address for Dobek and other Janux Therapeutics executives is , , . Janux Therapeutics can also be reached via phone at 858-751-4493 and via email at [email protected]. Learn More on Maria Dobek's contact information.
Has Maria Dobek been buying or selling shares of Janux Therapeutics?: In the last ninety days, Maria Dobek has sold $20,073.26 of Janux Therapeutics stock. Most recently, Maria Dobek sold 1,462 shares of the business's stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a transaction totalling $20,073.26. Following the completion of the sale, the vice president now directly owns 15,373 shares of the company's stock, valued at $211,071.29. Learn More on Maria Dobek's trading history.
Who are Janux Therapeutics' active insiders?: Janux Therapeutics' insider roster includes David Campbell (Founder, President & CEO), Thomas Diraimondo (Insider), Maria Dobek (VP), Zachariah Mciver (Insider), Andrew Meyer (Chief Business Officer), and Charles Winter (Insider). Learn More on Janux Therapeutics' active insiders.
Are insiders buying or selling shares of Janux Therapeutics?: During the last year, Janux Therapeutics insiders bought shares 2 times. They purchased a total of 451,948 shares worth more than $13,889,565.00. During the last year, insiders at the sold shares 12 times. They sold a total of 52,365 shares worth more than $1,286,149.42. The most recent insider tranaction occured on January, 2nd when insider Thomas Diraimondo sold 2,505 shares worth more than $34,393.65. Insiders at Janux Therapeutics own 29.4% of the company. Learn More about insider trades at Janux Therapeutics.
Information on this page was last updated on 1/2/2026.

Maria Dobek Insider Trading History at Janux Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/2/2026	Sell	1,462	$13.73	$20,073.26	15,373

Maria Dobek Buying and Selling Activity at Janux Therapeutics

Janux Therapeutics Company Overview

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Today's Range

Now: $13.49

$13.16

$13.53

50 Day Range

MA: $13.93

$12.18

$15.58

2 Week Range

Now: $13.49

$12.12

$38.42

Volume

221,964 shs

Average Volume

1,539,475 shs

Market Capitalization

$811.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.88